Seth Ginsberg: What Patients Need to Know About Biosimilars

Seth Ginsberg, co-founder and president of the Global Healthy Living Foundation, explains what patients should know about biosimilar therapies.
January 18, 2018


Transcript:

What are the most important things for patients to know about biosimilars?

For people with inflammatory arthritis like rheumatoid arthritis, or other chronic diseases that benefit from biologic medicines such as Crohn disease, psoriasis, [multiple sclerosis, MS], lupus, and others, biosimilars represent new treatment options simply because they are nearly identical to the originator biologic, but not exactly the same.

However, like with every medication, each patient will respond a little differently. Our advice is that patients with arthritis who are prescribed a biologic or biosimilar, track their response to treatment using our ArthritisPower research registry. Patients can download the free app and use it to enter their symptoms and treatment responses. They can also participate in arthritis research. It’s a great tool to understand how you are actually responding to a medicine (and other therapies) over time. Folks can learn more an download the app at www.ArthritisPower.org.
 

x-button

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.